CytoMed Therapeutics GDTC
NASDAQ GDTC
$0.91 +0.04 (+4.42%)
As of: Oct 21, 2026 · 3:59 PM EDT

CytoMed Therapeutics (GDTC) Operating Leases (2021 - 2026)

Updated

CytoMed Therapeutics' Operating Leases was $20,574 in Q2 2026, up 5.1% from $19,571 a year earlier.

Analysis

CytoMed Therapeutics (GDTC) Operating Leases (2021 - 2026) Analysis & Trends

At the end of FY2025, Operating Leases at CytoMed Therapeutics came in at $19,598, up 137.2% from FY2024.

  • Operating Leases shows a four-year compound annual growth rate of 25.8% (FY2021 to FY2025).
  • In earlier years, Operating Leases was $8,262 in FY2024 (+30.6%), $6,324 in FY2023 (-18.0%), $7,710 in FY2022 (-1.3%) and $7,813 in FY2021.
  • Quarterly Operating Leases has moved between $112.00 (Q2 2024) and $41,249 (Q4 2025) over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,170.86 Bn 1,139.45 Bn 19.71 Bn
2 Johnson & Johnson 639.81 Bn 558.34 Bn 17.26 Bn
3 AbbVie 501.68 Bn 474.79 Bn 12.70 Bn
4 Merck 374.79 Bn 329.16 Bn 12.21 Bn
5 Novartis Ag 302.69 Bn 266.68 Bn 11.24 Bn
6 Astrazeneca 268.27 Bn 241.96 Bn 12.86 Bn
7 Amgen 242.43 Bn 197.83 Bn 7.24 Bn
8 Gilead Sciences 193.38 Bn 167.58 Bn 6.22 Bn
9 Pfizer 172.45 Bn 119.10 Bn 10.94 Bn
10 CytoMed Therapeutics 10.29 Mn 1.11 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 20,574.00
Dec 31, 2025 41,639.53
Jun 30, 2025 19,571.00
Dec 31, 2024 16,941.45
Jun 30, 2024 2,565.00
Dec 31, 2023 6,324.00
Jun 30, 2023 7,506.00
Dec 31, 2022 4,993.60
Dec 31, 2021 11,330.64
API Access

CytoMed Therapeutics Operating Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-leases&ticker=GDTC&period=max&api_key=YOUR_API_KEY